- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.01. | Galecto-CEO Hans T. Schambye veräußert Aktien im Wert von 7.509 US-Dollar | 10 | Investing.com Deutsch | ||
| 11.12.24 | Galecto-Aktie erreicht 52-Wochen-Tief bei 5,26 US-Dollar | 4 | Investing.com Deutsch | ||
| 11.12.24 | Galecto stock hits 52-week low at $5.26 amid market challenges | 2 | Investing.com | ||
| GALECTO Aktie jetzt für 0€ handeln | |||||
| 26.11.24 | Galecto-Aktie erreicht 52-Wochen-Tief bei 5,51 US-Dollar | - | Investing.com Deutsch | ||
| 26.11.24 | Galecto stock hits 52-week low at $5.51 amid market challenges | 1 | Investing.com | ||
| 15.11.24 | Galecto-Aktie erreicht 52-Wochen-Tief bei 6,46 US-Dollar | 1 | Investing.com Deutsch | ||
| 15.11.24 | Galecto stock hits 52-week low at $6.46 amid market challenges | 4 | Investing.com | ||
| 01.11.24 | Galecto reports Q3 results | 2 | Seeking Alpha | ||
| 01.11.24 | Galecto, Inc.: Galecto Reports Third Quarter 2024 Financial Results | 148 | GlobeNewswire (Europe) | - Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets... ► Artikel lesen | |
| 01.11.24 | Galecto, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.10.24 | Galecto (NASDAQ:GLTO) Price Target Increased to $10.00 by Analysts at Oppenheimer | 6 | MarketBeat | ||
| 17.10.24 | Oppenheimer raises Galecto stock target, outperform on strategic focus | 9 | Investing.com | ||
| 15.10.24 | Galecto, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.10.24 | Galecto, Inc.: Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler | 3 | GlobeNewswire (USA) | ||
| 07.10.24 | Why Galecto (GLTO) Shares Are Down 27% Today | 3 | Benzinga.com | ||
| 07.10.24 | Galecto buys leukemia drug from Bridge Medicines, drops bone cancer asset in strategic pivot | 1 | FierceBiotech | ||
| 07.10.24 | Galecto To Focus On Clinical Stage Compound GB1211; Obtains Global Rights To BRM-1420 | - | RTTNews | ||
| 07.10.24 | Galecto, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.10.24 | Galecto fokussiert sich auf Krebs und erwirbt Rechte an neuartigem AML-Medikament | 16 | Investing.com Deutsch | ||
| 07.10.24 | Galecto, Inc.: Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines | 6 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,165 | +3,22 % | Kampf um Unabhängigkeit: Evotec: Der Chef hat das Strategie-Update angekündigt | © Foto: Christian Charisius/dpa - dpa-BildfunkEvotec kämpft um seine Unabhängigkeit. Vorstandschef Christian Wojczewski setzt auf eine Strategieüberprüfung und will im April erste Ergebnisse präsentieren.... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | Prusa gibt Update zum 3D-Drucker CORE One: Erste Auslieferungen stehen bevor | ||
| PALATIN TECHNOLOGIES | 0,923 | +0,65 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation zur Erkennung von fortgeschrittenen Adenomen in einer großen Patientenpopulation | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,260 | -0,86 % | Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week | ||
| TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| GALAPAGOS NV | 22,700 | -0,44 % | Galapagos inks agreement with Catalent for experimental CAR-T therapy | ||
| CENTOGENE | 0,120 | +20,00 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| AFFIMED | 1,045 | -1,42 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,232 | -0,85 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,492 | -1,40 % | Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones | - Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| AC IMMUNE | 2,640 | +1,34 % | AC Immune SA: AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome | AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious... ► Artikel lesen | |
| CHIMERIX | 3,670 | -0,27 % | Chimerix-Aktie erreicht 52-Wochen-Hoch bei 3,8 US-Dollar | ||
| CYTOMX THERAPEUTICS | 0,880 | +6,15 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update | - Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated... ► Artikel lesen | |
| CYTOKINETICS | 47,600 | +3,48 % | Cytokinetics, Incorporated: Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction | SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation... ► Artikel lesen |
GALECTO INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 5,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GALECTO INC finden Sie auf Wallstreet Online.
